Status:
ACTIVE_NOT_RECRUITING
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Lead Sponsor:
Celgene
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapse...
Eligibility Criteria
Inclusion
- Participant has a history of RRMM, and must:
- Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.
- Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.
Exclusion
- • Must not have previously received alnuctamab or mezigdomide.
- Note: Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
February 27 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2025
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT06163898
Start Date
February 27 2024
End Date
May 30 2025
Last Update
April 4 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0033
Birmingham, Alabama, United States, 35294
2
Local Institution - 0035
New Haven, Connecticut, United States, 06511
3
Local Institution - 0018
New York, New York, United States, 10065
4
Local Institution - 0021
Petah Tikva, Central District, Israel, 4910021